T

Tempus

AI-driven platform for medical data insights

Business Development Director - Multi-Omics, Government

Full-TimeUpdated on 10/23/2026
$150k - $200k+ Incentive compensation + Restricted stock units
Expert
Bachelor's, Master's, MBA, PhD
California, USA+2 moreMore locations: Washington, DC, USA | Illinois, USA
RemoteRemote roles are available in Illinois, California, and Washington, DC.
Sales & Account ManagementBusiness Development & Partnerships
No H1B Sponsorship
US Citizenship Required

About the job

Requirements
  • At least 10 years of experience working on U.S. federal projects or programs, including at least 5 years successfully serving in a Veterans Affairs business development or capture management role with a successful sales track record.
  • Ability to interact and influence collaboratively at the highest level of Veterans Affairs customer administrations.
  • Existing relationships with firms doing business with the Veterans Affairs and ability to form teaming partnerships.
  • Ability to lead proposal efforts, including capture, solutions, supporting business subject matter experts, technical experts, and clinical subject matter experts, proposal writing, and compliance review.
  • Ability to synthesize complex issues and communicate clearly.
  • Bachelor’s degree in a technical discipline; additional education, training, or experience may be considered in lieu of a degree.
  • At least 10 years in a business development position.
  • Proven track record of successful business development at a variety of acquisition sizes.
  • Demonstrated access to key customers and industry partners.
  • Excellent written and verbal communication skills.
  • Leadership skills to develop, organize, and execute significant business development activities, including building industry teams, assessing win probability, and executing customer call plans.
  • Prior experience supporting business development and capture efforts for health agencies.
  • Must be a U.S. citizen and eligible to obtain a security clearance.
Responsibilities
  • Build a healthy pipeline from inception to close by proactively identifying and shaping new business opportunities that leverage Tempus assets and capabilities.
  • Perform market research to qualify new business opportunities, including analysis of customer budgets, required capabilities, current customer preferences, the competitive environment, and incumbent strengths and weaknesses.
  • Coordinate and conduct meetings with customers, competitors, clients, and teammates to develop market insight on requirements, acquisition strategy, acquisition timing, and contract vehicle choices.
  • Work with program and management teams to develop and execute call plans, and provide detailed reports on follow-up activities after execution.
  • Serve as Capture Manager for selected opportunities, either through award or during the early capture phase.
  • Lead the business development process, including pipeline reviews, opportunity gate reviews, and proposal reviews.
  • Collaborate with account managers, project managers, other business development personnel, and functional partners such as marketing, regulatory, and research and development teams to win opportunities.
  • Prompt management, functional leads, other staff, and customers to build deep trust across stakeholders so customers extend their relationship and advocate for Tempus within their networks.
  • Advise senior management on opportunities to accelerate deal volume and velocity.
Desired Qualifications
  • Advanced degree (MBA, MS, or PhD) or healthcare certification.
  • At least 10 years of related strategic account experience in the healthcare diagnostic technology industry.
  • Diagnostics or genetic testing experience.
  • Strong business development, project management, time management, and organizational skills.
  • Strong understanding of the healthcare industry and competitive strategy techniques.
  • Experience with federal government budget, investments, and acquisition processes.
  • Ability to gain internal support, operate independently with limited supervision and feedback, and establish solid working relationships with technical staff, division managers, and peers.
  • Strong, respected relationships within Veterans Health (VBA and VHA) or other government agencies.
  • Ability to manage time independently without direct supervision.
  • Ability to operate at a senior level and influence, negotiate, and close.
  • Ability to obtain and maintain a Public Trust government security clearance.

About the company

T

Tempus

View
cbWebsite

Tempus provides an AI-powered platform that analyzes medical data and images to help physicians improve patient care and supports drug development for pharmaceutical and biotech companies. The platform produces actionable insights, finds gaps in care, and helps identify personalized therapy options for patients, while researchers use it for drug target discovery and evaluating treatments. It differentiates itself with a proprietary data-and-imaging platform paired with cancer-focused research tools, including a pan-cancer organoid platform and a validated liquid biopsy assay for profiling circulating tumor DNA. Its goal is to improve patient outcomes through data-driven, personalized medicine and to speed cancer research and development.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Get referred to Tempus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus raised 2026 revenue guidance to $1.595 billion-$1.605 billion after Q2 momentum.
  • ARPA-H awarded Tempus up to $9.5 million for heart-failure AI on September 9, 2026.
  • Tempus launched a 100,000-genome dataset, with general availability targeted for mid-2027.

What critics are saying

  • Guardant Health's Delaware patent suits seek injunctions against xF and xM tests.
  • Farrier v. Tempus AI alleges genetic-data misuse under Illinois GIPA since February 2026.
  • Autonomous heart-failure AI needs FDA authorization within 24 months, exposing Tempus to regulatory failure.

What makes Tempus unique

  • Tempus pairs multimodal records, pathology, genomics, and longitudinal outcomes at scale.
  • Tempus earned four FDA-cleared ECG AI products by September 2026.
  • Leica Biosystems added Tempus Paige products to Aperio AI Store on September 24, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Relocation Assistance
  • Company Equity
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
MarketScreener
Oct 23rd, 2026
Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research.

Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research. Pathos AI announced a partnership with Bristol Myers Squibb and Tempus AI to harness artificial intelligence in the development of treatments for Alzheimer's disease and other neurological disorders. The collaboration comes with a $237m Series E funding round led by Bristol Myers Squibb, valuing the New York-based company at approximately $3bn. The transaction aims to strengthen Pathos AI's research capabilities and accelerate the identification of new therapeutic avenues through the analysis of large-scale medical data. Published on 10/23/2026 at 10:57 am EDT MarketScreener.com Under the agreement, Tempus AI will build a database covering several hundred thousand patients with neurological diseases, which Pathos AI will be able to access for five years in exchange for $55m. The information will be analyzed by its Pathos Foundry platform to gain a better understanding of the biological mechanisms behind diseases, identify potential treatments and improve the design of clinical trials. Bristol Myers Squibb will receive strategic, nonexclusive access to the technology across all of its research and development activities, as well as exclusive rights for three years to its neuroscience programs. The $237m raised will also enable Pathos AI to develop its platform and advance its pipeline of experimental drugs. The projects involved include JSKN016, an experimental cancer treatment, as well as a breast cancer program being conducted with AstraZeneca. The strategy reflects the company's intention to expand the use of artificial intelligence beyond neurological diseases, particularly in oncology. For the three partners, the goal is to make better use of medical data to accelerate drug discovery and make clinical trials more precise and better suited to patients. (C) MarketScreener.com - 2026

MarketScreener
Oct 23rd, 2026
Tempus AI expands Bristol Myers partnership with multi-year oncology, AI data deals.

Tempus AI expands Bristol Myers partnership with multi-year oncology, AI data deals. Published on 10/23/2026 at 10:32 am EDT - Modified on 10/23/2026 at 10:37 am EDT By Adriano Marchese Tempus AI signed a multi-year deal with Bristol Myers Squibb to license oncological data and provide access to its artificial intelligence-powered platform. Under the terms of the deal, Bristol Myers will gain access to Tempus's Lens Platform, the company's agentic AI platform for oncology drug development, which is built on real-world multimodal datasets. The agreement will run through 2031 to support biological and clinical insight, novel drug target discovery and therapeutic development across the pharmaceutical company's oncology portfolio. Additionally, clinical-stage technology firm Pathos AI is also broadening its strategic collaborations with both Bristol Myers and Tempus AI. The collaboration aims to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. Bristol Myers led a $237 million Series E financing round for Pathos at a $3 billion valuation, gaining rights to Pathos' Foundry AI platform and broader portfolio. According to a regulatory filing on Friday, the combined agreements provide Tempus with $192.5 million in total cash commitments over five years, consisting of $137.5 million directly from Bristol Myers, and $55 million from Pathos AI for 500,000 de-identified patient records. Write to Adriano Marchese at [email protected] (END) Dow Jones Newswires 10-23-26 1031ET (C) Dow Jones - 2026

941 The Duke
Oct 23rd, 2026
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development.

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development. By Thomson Reuters Oct 23, 2026 | 9:00 AM Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors. Here are some other details: - Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology - Pathos will license the data from Tempus under a five-year, $55 million agreement - Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials - Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs - Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016 - The funding will help advance development of other cancer programs including an AstraZeneca-partnered experimental breast cancer drug (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)

BioPharma Watch
Oct 7th, 2026
Tempus announces multi-year collaboration with Moderna and Merck.

Tempus announces multi-year collaboration with Moderna and Merck. Key Takeaway: Tempus has announced a multi-year collaboration with Moderna and Merck to support the commercialization of intismeran autogene, a novel individualized neoantigen therapy. This therapy is being evaluated in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma and other cancers. The collaboration signifies a significant step in cancer treatment innovation. Market sentiment analysis. Positive factors. * Collaboration aims to support commercialization of innovative therapy. * Intismeran autogene is a potential first-in-class treatment. * Combination therapy with KEYTRUDA may enhance cancer treatment options. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 9 past catalysts Cash runway Minimal dilution risk Lead asset Phase 2 · Influenza CHICAGO-(BUSINESS WIRE)-Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA(R)(pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know Frequently asked questions. What is the focus of the Tempus collaboration? The collaboration focuses on supporting the commercialization of intismeran autogene. Which therapy is intismeran autogene combined with? Intismeran autogene is evaluated in combination with KEYTRUDA. What types of cancer are targeted in this collaboration? The collaboration targets completely resected stage IIB-IV melanoma and other cancers. Who are the partners in the collaboration? The partners are Tempus, Moderna, and Merck.

Pathology in Practice
Sep 25th, 2026
Leica Biosystems adds Paige products to Aperio AI Store

Leica Biosystems adds Paige products to Aperio AI Store. * September 25, 2026 Leica Biosystems has added two Paige digital pathology AI-enabled products from Tempus to its growing Aperio AI Store - a unified, interoperable digital pathology platform that provides multiple AI-powered applications in a single interface. Designed to simplify adoption and accelerate the use of advanced image analysis, the Aperio AI Store helps turn complex pathology images into actionable research insights that could ultimately drive the future of patient care. By bringing leading partner applications into a streamlined workflow, the Aperio AI Store helps laboratories and researchers generate insights from pathology images more efficiently and at scale, supporting broader adoption of computational pathology and helping unlock the full value of digital pathology data for cancer research. The newly available products include Paige PanCancer Detect, a groundbreaking research application designed to identify suspicious areas across more than 40 cancer types, powered by Tempus' pathology foundation model. The release also features Paige Prostate, a suite of AI-powered research applications - including Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Perineural Invasion - that support the assessment of prostate cancer features in H&E-stained whole-slide images. Both products are for research use only and are not intended for diagnostic or clinical use. As digital pathology adoption grows, pathologists need AI tools that integrate naturally into existing workflows. The Aperio AI Store is designed to simplify and scale AI adoption by bringing partner algorithms directly into the Aperio HALO AP software workflow. Instead of navigating separate software interfaces for each algorithm or vendor, users can access a broad and growing selection of curated AI applications through one consistent experience. For laboratories evaluating multiple AI tools across diverse case types, this approach can help reduce complexity and support more efficient adoption. "Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "Tempus brings highly differentiated AI capabilities to our ecosystem, giving laboratories more choice while allowing them to access these technologies within a workflow they already know. This is an important step toward making AI more practical, scalable, and ultimately more impactful in pathology." Available exclusively through the Aperio HALO AP image management system, the Aperio AI Store has gained momentum since its U.S. launch in October 2025 by offering a practical suite of AI tools within a pathologist-centric, interoperable digital pathology workspace. Aperio HALO AP is developed in partnership with Indica Labs. In the USA Aperio HALO AP is For Research Use Only. Not for use in diagnostic procedures. Aperio HALO AP is CE-IVDR marked in the EU. All other products are For Research Use Only. Not for use in diagnostic procedures.